On July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb), the first medicine shown to delay the course of the disease.

Having gone through a rigorous approval process, the medication exemplifies a critical advancement in the ongoing battle to treat Alzheimer’s disease.

Dr. Robert Przybelski, director of Geriatric Memory Clinics UW Health, profession of the Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health, has already prescribed the treatment to real-life patients.

Dr. Przybelski joins the podcast to discuss his experience prescribing and administering lecanemab, what clinicians and patients should discuss when considering these treatments, and what is needed to integrate these treatments into the healthcare system.

SOURCE:

Wisconsin Alzheimer’s Disease Research Center YouTube Channel